- Home
- PETZ vs EDSA Comparison
PETZ vs EDSA Comparison
Compare PETZ & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- EDSA
- Stock Information
- Founded
- PETZ 2002
- EDSA 2015
- Country
- PETZ China
- EDSA Canada
- Employees
- PETZ N/A
- EDSA N/A
- Industry
- PETZ Steel/Iron Ore
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- EDSA Health Care
- Exchange
- PETZ Nasdaq
- EDSA Nasdaq
- Market Cap
- PETZ 12.9M
- EDSA 11.0M
- IPO Year
- PETZ 2017
- EDSA N/A
- Fundamental
- Price
- PETZ $1.20
- EDSA $2.09
- Analyst Decision
- PETZ
- EDSA Strong Buy
- Analyst Count
- PETZ 0
- EDSA 1
- Target Price
- PETZ N/A
- EDSA $21.00
- AVG Volume (30 Days)
- PETZ 19.7K
- EDSA 50.3K
- Earning Date
- PETZ 11-26-2024
- EDSA 12-13-2024
- Dividend Yield
- PETZ N/A
- EDSA N/A
- EPS Growth
- PETZ N/A
- EDSA N/A
- EPS
- PETZ N/A
- EDSA N/A
- Revenue
- PETZ $3,175,809.00
- EDSA N/A
- Revenue This Year
- PETZ N/A
- EDSA N/A
- Revenue Next Year
- PETZ N/A
- EDSA N/A
- P/E Ratio
- PETZ N/A
- EDSA N/A
- Revenue Growth
- PETZ 2.49
- EDSA N/A
- 52 Week Low
- PETZ $0.89
- EDSA $2.09
- 52 Week High
- PETZ $1.74
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- PETZ 41.14
- EDSA 19.32
- Support Level
- PETZ $1.20
- EDSA $2.26
- Resistance Level
- PETZ $1.30
- EDSA $2.44
- Average True Range (ATR)
- PETZ 0.06
- EDSA 0.26
- MACD
- PETZ -0.01
- EDSA -0.06
- Stochastic Oscillator
- PETZ 4.76
- EDSA 0.00
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.